These data indicate that a combination of USP2 inhibition and PD-1/PD-L1 blockade potently suppresses tumor growth in vivo, and that the contribution of USP2 inhibition to this effect is dependent on the tumor cell autonomous activity of p53. Here, USP2 is linked to neoplasm.